chronic-diseases-2017-posters-accepted-abstracts

19 / 22

Volume 2, Issue 2 (Suppl) Chronic Obstructive Pulmonary Diseases
ISSN: 2572-5548
Page 66
conferenceseries.com
CO-ORGANIZED EVENT
August 31-September 01, 2017 Brussels, Belgium
&
International Conference on Chronic Diseases
6th International Conference on Microbial Physiology and Genomics
Feasibility and acceptability of mindfulness-based cognitive therapy in people with depression and
cardiovascular disorders: Feasibility randomized controlled trial
Modi Alsubaie1, Chris Dickens 1, Barnaby D Dunn1, Andy Gibson2, Obioha C Ukoumunne1, Alison Evans1, Rachael Vicary1, Manish Gandhi3 and Willem
Kuyken4
1University of Exeter, UK
2University of the West of England, UK
3Royal Devon and Exeter Hospital, UK
4University of Oxford, UK
Background: Depression co-occurs in 20% of people with cardiovascular disorders, can persist for years, and predicts worse
physical health outcomes. While psychosocial treatments have been shown to effectively treat acute depression in those with
comorbid cardiovascular disorders, to date there has been no evaluation of approaches aiming to prevent relapse and treat
residual depression symptoms in this group. Therefore, the current study aimed to examine the feasibility and acceptability of
a randomized controlled trial design evaluating an adapted version of mindfulness-based cognitive therapy (MBCT) designed
specifically for people with co-morbid depression and cardiovascular disorders.
Methods: A 3-arm feasibility randomized controlled trial was conducted, comparing MBCT adapted for people with
cardiovascular disorders plus treatment as usual (TAU), mindfulness-based stress reduction (MBSR) plus TAU, and TAU
alone. Participants completed a set of self-report measures of depression severity, anxiety, quality of life, illness perceptions,
mindfulness and self-compassion, and had their blood pressure taken immediately before, immediately after, and three months
following the intervention. Those in the adapted-MBCT arm additionally underwent a qualitative interview to gather their
views about the adapted intervention.
Results: 3400 potentially eligible participants were approached when attending an outpatient appointment at a cardiology
clinic or via a GP letter following a case note search. 242 (7.1%) were interested in taking part, 59 (1.7%) were screened as being
suitable, and 33 (<1%) were eventually randomized to the three groups. The sample was heterogeneous in terms of whether
they reported current depression or had a history of depression and the time since the onset of cardiovascular disease (one
to 25 years). Of 11 participants randomized to adapted MBCT seven completed the full course, levels of home mindfulness
practice were high, and positive qualitative feedback about the intervention was given. 29 out of 33 participants randomized
completed all the assessment measures at all three time points. With regards to the primary outcome (depression), five out
of the seven people who completed the adapted MBCT and three out of five under MBSR showed significant clinical change,
while in TAU no one showed any clinical change at the three-month follow-up.
Conclusions: The adapted MBCT intervention was feasible and acceptable to participants. However, aspects of the trial design
were not feasible. In particular, low recruitment rates were achieved and there was a high withdrawal rate between screening
and randomization. Moreover, the heterogeneity in the sample was high meaning the adapted intervention was unlikely to be
well tailored to all participants needs. This suggests that if the decision is made to move to a definitive trial, study recruitment
procedures will need to be revised to more successfully recruit a target sample that optimally matches the adapted intervention.
Chron Obstruct Pulmon Dis 2017, 2:2
DOI: 10.21767/2572-5548-C1-003